Biology Reference
In-Depth Information
[82] Cooke KR, Hill GR, Gerbitz A, Kobzik L, Martin TR, Crawford JM, et al. Tumor necrosis
factor-alpha neutralization reduces lung injury after experimental allogeneic bone
marrow transplantation. Transplantation 2000;70:272-9.
[83] Krijanovski OI, Hill GR, Cooke KR, Teshima T, Crawford JM, Brinson YS, et al. Kerati-
nocyte growth factor separates graft-versus-leukemia effects from graft-versus-host
disease. Blood 1999;94:825-31.
[84] Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, et al. A biomark-
er panel for acute graft-versus-host disease. Blood 2009;113:273-8.
[85] Bouazzaoui A, Spacenko E, Mueller G, Miklos S, Huber E, Holler E, et al. Chemokine
and chemokine receptor expression analysis in target organs of acute graft-versus-host
disease. Genes Immun 2009;10:687-701.
[86] Schneider MA, Meingassner JG, Lipp M, Moore HD, Rot A. CCR7 is required for the
in vivo function of CD4+ CD25+ regulatory T cells. J Exp Med 2007;204:735-45.
[87] de Jager SC, Cante-Barrett K, Bot I, Husberg C, van Puijvelde GH, et al. Impaired ef-
fector memory T-cell regulation facilitates graft versus host disease in CCR7-deficient
bone marrow transplant chimeras. Transplantation 2009;88:631-9.
[88] Wysocki CA, Jiang Q, Panoskaltsis-Mortari A, Taylor PA, McKinnon KP, Su L, et al. Criti-
cal role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute
graft-versus-host disease. Blood 2005;106:3300-7.
[89] Varona R, Cadenas V, Lozano M, Moreno-Ortiz MC, Kremer L, Martinez AC, et al. CCR6
regulates the function of alloreactive and regulatory CD4+ T cells during acute graft-
versus-host disease. Leuk Lymphoma 2006;47:1469-76.
[90] Hasegawa H, Inoue A, Kohno M, Lei J, Miyazaki T, Yoshie O, et al. Therapeutic effect of
CXCR3-expressing regulatory T cells on liver, lung and intestinal damages in a murine
acute GVHD model. Gene Ther 2008;15:171-82.
[91] Kunkel EJ, Campbell JJ, Haraldsen G, Pan J, Boisvert J, Roberts AI, et al. Lymphocyte CC
chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expres-
sion distinguish the small intestinal immune compartment: epithelial expression of
tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med
2000;192:761-8.
[92] Zabel BA, Agace WW, Campbell JJ, Heath HM, Parent D, Roberts AI, et al. Human G pro-
tein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on in-
testinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required
for thymus-expressed chemokine-mediated chemotaxis. J Exp Med 1999;190:1241-56.
[93] Inamoto Y, Murata M, Katsumi A, Kuwatsuka Y, Tsujimura A, Ishikawa Y, et al. Donor
single nucleotide polymorphism in the CCR9 gene affects the incidence of skin GVHD.
Bone Marrow Transplant 2010;45:363-9.
[94] Faaij CM, Lankester AC, Spierings E, Hoogeboom M, Bowman EP, Bierings M, et al.
A possible role for CCL27/CTACK-CCR10 interaction in recruiting CD4 T cells to skin in
human graft-versus-host disease. Br J Haematol 2006;133:538-49.
[95] Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-ver-
sus-host disease, each with distinct end-organ targets. J Clin Invest 2000;105:1289-98.
[96] Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-
versus-host disease, a model for human scleroderma: cutaneous cytokines, chemo-
kines, and immune cell activation. J Immunol 2002;168:3088-98.
[97] Zhou L, Askew D, Wu C, Gilliam AC. Cutaneous gene expression by DNA microarray in
murine sclerodermatous graft-versus-host disease, a model for human scleroderma.
J Invest Dermatol 2007;127:281-92.
[98] Sasaki M, Hasegawa H, Kohno M, Inoue A, Ito MR, Fujita S. Antagonist of secondary
lymphoid-tissue chemokine (CCR ligand 21) prevents the development of chronic
graft-versus-host disease in mice. J Immunol 2003;170:588-96.
[99] Westekemper H, Meller S, Citak S, Schulte C, Steuhl KP, Homey B, et al. Differential
chemokine expression in chronic GVHD of the conjunctiva. Bone Marrow Transplant
2010;45:1340-6.
[100] Arpinati M, Chirumbolo G, Marzocchi G, Baccarani M, Rondelli D. Increased donor
CD86+CD14+ cells in the bone marrow and peripheral blood of patients with chronic
graft-versus-host disease. Transplantation 2008;85:1826-32.
[101] Kim DH, Jung HD, Lee NY, Sohn SK. Single nucleotide polymorphism of CC chemokine
ligand 5 promoter gene in recipients may predict the risk of chronic graft-versus-host
disease and its severity after allogeneic transplantation. Transplantation 2007;84:917-25.
[102] Morita NI, Matsumura Y, Morita K, Miyachi Y. Expression of CCR5 in graft-versus-host
disease (GVHD) of the skin: immunohistochemical staining of 38 cases. J Dermatol
2007;34:254-7.
[103] Schneider GP, Salcedo R, Welniak LA, Howard OM, Murphy WJ. The diverse role of
chemokines in tumor progression: prospects for intervention (review). Int J Mol Med
2001;8:235-44.
423
Search WWH ::
Custom Search